A therapeutic dendritic cell-based vaccine for HIV-1 infection

Journal of Infectious Diseases

Volumn 203, Issue 4, 2011, Pages 473-478

  García, Felipe ^a   Climent, Núria ^a   Assoumou, Lambert ^f   Gil, Cristina ^a   González, Nuria ^c   Alcamí, José ^c   León, Agathe ^a   Romeu, Joan ^d   Dalmau, Judith ^e   Martínez Picado, Javier ^b,e   Lifson, Jeff ^h   Autran, Brigitte ^g   Costagliola, Dominique ^f   Clotet, Bonaventura ^d,e   Gatell, Josep M ^a   Plana, Montserrat ⁱ   Gallart, Teresa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e IrsiCaixa Foundation   (Spain)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h SAIC FREDERICK INC   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DENDRITIC CELL VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHADENOPATHY; MALE; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; AIDS VACCINES; DENDRITIC CELLS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RNA, VIRAL; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79751500441     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq077     Document Type: Article

References (18)

1. Kundu SK, Engleman E, Benike C, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998; 14:551-60. (Pubitemid 28196782)
2. Lu W, Arraes L, Ferreira W, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-65. (Pubitemid 40022718)
3. García F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J Infect Dis 2005; 195:1680-5. (Pubitemid 40656756)
4. Ide F, Nakamura T, Tomizawa M, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006; 78:711-8.
5. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008; 15:284-92. (Pubitemid 352025534)
6. Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009; 27:6088-94.
7. Kloverpris H, Karlsson I, Bonde J, et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009; 23:1329-40.
8. Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-7.
9. Fenyo EM, Heath A, Dispinseri S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. LoS One 2009; 4:e4505.
10. Lopez A, van der Lubbe N, Sanchez-Palomino S, et al. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 2009; 27:6166-78.
11. Plana M, Garcia F, Oxenius A, et al. Relevance of HIV-1-specific CD4+ T helper cell responses during structured treatment interruption in patients with a nadir CD4 T cells above 400/mm3. J Acquir Immune Defic Syndr 2004; 36:791-9. (Pubitemid 38859344)
12. Frank I, Piatak M Jr., Stoessel H, et al. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J Virol 2002; 76:2936-51. (Pubitemid 34184879)
13. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004; 103:2648-54. (Pubitemid 38393020)
14. Lu W, Andrieu JM. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001; 75:8949-56.
15. Buseyne F, Le GS, Boccaccio C, et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001; 7:344-9. (Pubitemid 32224351)
16. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37:1095-101. (Pubitemid 23141326)
17. Rodriguez-Garcia M, Climent N, Oliva H, et al. Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. PLoS One 2010; 5:e9436.
18. Kinloch-De LS, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005;192: 607-17. (Pubitemid 41099309)